IDO is also overexpressed Hodgkin and NHL and IDO expression in tumor tissue of DLBCL can stratify patients at risk for chemotherapy resistance and decreased survival [175–179]. This evidence concerns the gene IDO1 and non-Hodgkin lymphoma.